• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Artemisinin-based antimalarials may be safe and efficacious in pregnant women

byShayna BejaimalandMarc Succi, MD
March 11, 2016
in Infectious Disease, Obstetrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 

1. All four artemisinin-based treatment groups had cure rates of over 94%. Artemether-lumefantrine was statistically less efficacious than the other three regimens however was only less efficacious by 2%.

2. Rates of serious adverse events were not statistically significant across the four treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Little information is known about the efficacy and toxicity of new anti-malaria treatment options in pregnant women. Given the risk of maternal anemia and infant mortality in pregnant women with malaria, it is important to study the new Artemisinin-based combination therapies in pregnant women to ensure their safe use. This study aimed to determine the safety and efficacy profile of four Artemisinin-based antimalarial treatments African pregnant women.

All treatment groups provided polymerase-chain-reaction (PCR)-adjusted cure rates above 94%. However, statistically, the artemether-lumefantrine group did poorer as compared to amodiaquine-artesunate, mefloquine-artesunate or dihydroartemisinin-piperaquine. There were no significant differences in serious adverse events across all treatment groups. Strengths of this study include a large sample size of an often-underrepresented study population. Limitations noted include the lack of double-blinding and comparative placebo control group for assessment of efficacy.

Click to read the study, published today in NEJM

RELATED REPORTS

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

Chlorfenapyr insecticidal nets provide strong protection against malaria in sub-Saharan Africa

Mosquito Nets Provide Survival Benefit in Early Childhood and into Adulthood

Click to read an accompanying editorial in NEJM

Relevant Reading: Malaria in pregnancy

In-Depth [randomized controlled trial]: This randomized, open-label controlled trial was conducted between June 2010 and August 2013 in seven sites in four sub-Saharan African countries (Burkina Faso, Ghana, Malawi, Zambia). The study population included pregnant women in the second or third trimester who had Plasmodium falciparum monoinfection, hemoglobin >70g/L and no other serious illnesses. These women were randomly assigned to one of four treatment groups: artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate or dihydroartemisinin-piperaquine. The primary endpoint of interest was PCR-adjusted cure rates at day 63 and safety outcomes. The primary statistical analysis was a per-protocol method.

A total of 3428 pregnant women were enrolled and randomized to the four treatment groups: artemether-lumefantrine (881 women), amodiaquine-artesunate (843), mefloquine-artesunate (849) or dihydroartemisinin-piperaquine (855). The PCR-adjusted cure rates in the per-protocol analysis was 94.8% in artemether-lumefantrine, 98.5% in amodiaquine-artesunate, 96.8% in mefloquine-artesunate and 99.2% in the dihydroartemisinin-piperaquine treatment group. There was no significant difference in treatment efficacy among amodiaquine-artesunate, mefloquine-artesunate or dihydroartemisinin-piperaquine however the cure rate was significantly lower in the artemether-lumefantrine group. There was no significant difference in the rate of serious adverse events or birth outcomes across all treatment groups.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: malaria
Previous Post

Patient and care transitions factors play role in preventable hospital readmissions

Next Post

Younger sibling presence associated with improved BMI trajectory

RelatedReports

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Chronic Disease

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

April 22, 2022
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Infectious Disease

Chlorfenapyr insecticidal nets provide strong protection against malaria in sub-Saharan Africa

April 6, 2022
Intrauterine Zika virus infection associated with significant fetal brain abnormalities
Infectious Disease

Mosquito Nets Provide Survival Benefit in Early Childhood and into Adulthood

February 8, 2022
#VisualAbstract: Tezepelumab reduced annual exacerbation rates in patients with severe asthma
StudyGraphics

#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children

June 3, 2021
Next Post
Younger sibling presence associated with improved BMI trajectory

Younger sibling presence associated with improved BMI trajectory

Food environment associated with gestational diabetes

Intranasal glucagon may be effective in the treatment of hypoglycemia in type 1 diabetes

Late pregnancy pertussis vaccination may boost passive immunity

Late pregnancy pertussis vaccination may boost passive immunity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.